In February 17 ITL recorded its highest monthly revenue and profit, and began initial supply of products under the global distribution deal with bioMérieux. They've also just signed a new deal with the NZ Blood service.
However, yesterday the Boat Fund released a report estimating FY17 EPS of 4.2c.
Can anyone help me understand why FY EPS is not at least double H1 EPS considering the record months and new deals?
ITD Price at posting:
52.5¢ Sentiment: None Disclosure: Not Held
